Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

•First long-term OS data of erlotinib + bevacizumab vs erlotinib in this population.•Both treatment arms showed a similar median OS of approximately 4 years.•Results of EGFR and VEGF inhibitor combination therapies are eagerly awaited.